Comparative Biochemical Outcomes, Effectiveness and Tolerance of Densiron 68 and Oxane HD for the Management of Complicated Retinal Detachment

Autor: Keilani C; Quinze-Vingts National Hospital, Department of Ophthalmology IV / Sorbonne University, Faculty of Medicine Pierre-et-Marie-Curie/Assistance Publique-Hopitaux de Paris, Paris, France, Augstburger E; Quinze-Vingts National Hospital, Department of Ophthalmology III, Paris, France, Robin M; Quinze-Vingts National Hospital, Department of Ophthalmology III, Paris, France, Beaugrand A; Quinze-Vingts National Hospital, Department of Biomedical Informatics, Paris, France, Ores R; Quinze-Vingts National Hospital, Department of Ophthalmology, Paris, France, Sahel JA; Quinze-Vingts National Hospital, Department of Ophthalmology, Paris, France, Ayello-Scheer S; Quinze-Vingts National Hospital, Department of Ophthalmology, Paris, France
Jazyk: angličtina
Zdroj: Turkish journal of ophthalmology [Turk J Ophthalmol] 2019 Dec 31; Vol. 49 (6), pp. 334-341.
DOI: 10.4274/tjo.galenos.2019.24294
Abstrakt: Objectives: To compare biochemical outcomes, effectiveness, and tolerance of two high-density silicone oils (HDSOs), silicone oil- RMN3 (Oxane ® HD) and silicone oil-Densiron-68 (Densiron ® 68), for the management of complicated retinal detachment (RD) associated with inferior proliferative vitreoretinopathy (PVR).
Materials and Methods: This was a retrospective, single-centre, comparative case series of 23 patients treated between September 2014 and June 2016. The main inclusion criteria were RD with inferior PVR receiving Oxane ® HD or Densiron ® 68 following pars plana vitrectomy. The main outcome measures were anatomical success, rate of RD recurrence, and best-corrected visual acuity (BCVA) at 6 months. Secondary outcomes were short-term complications.
Results: Twenty-three eyes were included: 16 eyes with Densiron ® 68 tamponade and 7 eyes with Oxane ® HD tamponade. Anatomical success under HDSO was significantly higher in the Densiron ® 68 group (100%) than in the Oxane ® HD group (42.8%) (p=0.0455). Recurrent RD was observed in 42.8% of eyes under Oxane ® HD, but in none of the patients under Densiron ® 68 (p=0.001). Six months after surgery, mean BVCA values (+/- standard deviation) with Densiron ® 68 and Oxane ® HD were 0.83±0.62 logMAR and 1.81±0.65 logMAR, respectively. BVCA was significantly better in the Densiron ® 68 group (p=0.006). No significant differences were observed with regard to intraocular pressure, emulsification, or intraocular inflammation.
Conclusion: Densiron ® 68 appears to be more effective than Oxane ® HD for the management of RD associated with PVR. A randomized, controlled, interventional study is needed to demonstrate this difference.
Databáze: MEDLINE
Externí odkaz: